Motif BioSciences, Inc.
Motif BioSciences, Inc. (“Motif”) works with a variety of Founder Populations to accelerate discovery of genetic variation involved in common diseases. Motif’s approach stacks the odds for making discoveries – using the right population, right cases and controls, and the right technology.
Over the next few years, more than half the world’s top selling drugs will go off patent. Motif’s business aims are to meet the needs of the pharmaceutical and diagnostic companies through:
-
Developing new pathways for discovery and as targets for new drug development,
-
Partnering with diagnostic companies to develop Motif’s genetic information into disease risk assessment tests and treatment profiling tests, and
-
In partnership with pharmaceutical companies launch a re-profiling programme on late-stage drug failures to enable regulatory approval on a genetically-defined sub-group of patients in which the drug is efficacious.
By applying its expertise, skills, and proprietary technology to specific populations, Motif expects to make important discoveries on the genetic basis of diseases such as diabetes, asthma, and cancer and to develop the commercial value of these discoveries by partnering with pharmaceutical and diagnostic companies.
Amphion’s fully-diluted ownership stake in Motif was 37.69% as of 31 December 2007, valued at US $12.8 million (2006: US $10.3 million).
Management
Zaki Hosny, Chief Executive Officer
Clay Stephens, Ph.D, Senior Vice President and Chief Scientific Officer
Kevin Arnold, Ph.D, Executive Director, Industrial Genetics
Board of Directors
Richard C.E. Morgan, Chairman – Chief Executive Officer, Amphion Innovations plc
Omar Ghobash – Deputy Chief Executive Officer, Gulf Target Group
Jon Gold – Senior Financial Analyst, Federated Investments Inc.
Gerard Moufflet – Chief Executive Officer and President, Acceleration International
Dr. Mary Lake Polan – Board of Directors, Wyeth Corporation, Formally Professor and Chair emeritus, Department of Obstetrics and Gynecology, Stanford University School of Medicine
Dr. John Stakes – Director of Specialty Care Development, Harvard Medical School and Massachusetts General Hospital
Bruce Williams – Biotechnology Industry Consultant, Formally held senior marketing positions at Celgene Corp., and Ortho Biotech, a Johnson&Johnson company
